Yarrow Bioscience Inc (YARW) Stock Analysis

What Yarrow Bioscience Inc does

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

Key metrics

ETFs linked to YARW

Broad-market and Healthcare sector ETFs an investor holding Yarrow Bioscience Inc is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how YARW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Yarrow Bioscience Inc?

Yarrow Bioscience Inc trades under the ticker YARW on NASDAQ.

Which exchange is YARW listed on?

YARW is listed on NASDAQ.

What sector does Yarrow Bioscience Inc operate in?

Yarrow Bioscience Inc is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze YARW in a portfolio?

PortView shows YARW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.